Standout Papers

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease 2025 202620
  1. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease (2025)
    Jeffrey L. Cummings, Alireza Atri et al. Alzheimer s Research & Therapy

Immediate Impact

62 standout
Sub-graph 1 of 23

Citing Papers

GLP-1-based therapies for diabetes, obesity and beyond
2025 Standout
Do the benefits outweigh the disadvantages? Exploring the role of artificial intelligence in renewable energy
2024 Standout
2 intermediate papers

Works of Teresa León being referenced

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
2025 Standout
Assessing energy forecasting inaccuracy by simultaneously considering temporal and absolute errors
2017

Author Peers

Author Last Decade Papers Cites
Teresa León 197 63 95 291 120 41 738
H. Hasan Örkçü 97 31 52 325 101 46 656
Jakub Więckowski 138 38 46 386 100 55 714
Ali Ala 92 43 18 125 111 39 813
Sajid Siraj 101 77 39 345 108 29 761
Simona Dziţac 127 37 29 183 81 50 746
Chunming Ye 118 58 25 129 103 75 829
Prasun Kumar Nayak 170 86 131 195 37 33 693
Kuo-Chen Hung 107 75 121 366 170 45 750
Zia Bashir 177 166 123 424 222 42 811
Sangeeta Pant 88 61 37 105 152 32 717

All Works

Loading papers...

Rankless by CCL
2026